Physician profile
Matthew D Eagleson
NPI 1295020048
$7,106.64
in general payments reported to CMS, 2019-2025
23 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,858 · 2020: $492 · 2021: $559 · 2022: $343 · 2023: $486 · 2024: $851 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,854.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $3,836.02 | 2019-2020 | |
| Medtronic, INC. | $1,229.43 | 2021-2025 | Intellis Adaptivestim, Activos 10 Bone Cement, Accurian |
| Nevro Corp. | $728.60 | 2019-2024 | Senza |
| Abbvie INC. | $328.67 | 2022-2025 | Botox |
| Globus Medical, INC. | $161.71 | 2025 | Vyrsa V1, Vyrsa V1, Senza |
| Vertiflex, INC. | $125.15 | 2019 | |
| Abbott Laboratories | $114.22 | 2019-2023 | Proclaim |
| Amgen INC. | $76.50 | 2021-2022 | |
| Stryker Corporation | $65.41 | 2019-2025 | |
| Allergan, INC. | $63.13 | 2021-2022 | |
| Vertos Medical, INC. | $40.35 | 2023-2024 | Mild Device Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $38.29 | 2022 | |
| Collegium Pharmaceutical, INC. | $37.88 | 2024-2025 | Belbuca |
| Bioventus LLC | $36.24 | 2025 | Durolane, Gelsyn-3 |
| Alvogen INC | $33.60 | 2023 | Teriparatide |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $33.05 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $31.33 | 2021 | |
| Si-Bone, INC. | $26.68 | 2024 | |
| Averitas Pharma INC. | $24.13 | 2025 | Qutenza |
| Zak Ortho | $23.05 | 2025 | |
| Spr Therapeutics, INC | $18.83 | 2020 | |
| Boston Scientific Corporation | $17.68 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Eagleson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.